Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Goes Boldly Into Immuno-Neurology With Alector

Executive Summary

AbbVie agreed to pay $205m up front to biotech start-up Alector to research a portfolio of antibody targets to treat Alzheimer's and other neurodegenerative diseases by harnessing the immune system.

You may also be interested in...



Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B

Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.

Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m

Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel